Date: Fri, 11 Jun 2010 08:40:57 -0600
Reply-To: DCHAS-L Discussion List <DCHAS-L**At_Symbol_Here**LIST.UVM.EDU>
Sender: DCHAS-L Discussion List <DCHAS-L**At_Symbol_Here**LIST.UVM.EDU>
From: Alan Hall <ahalltoxic**At_Symbol_Here**MSN.COM>
Subject: Re: toxicity question
In-Reply-To: <F5D83326DC77FD4EA138E9194D6B28883371E835D5**At_Symbol_Here**>

Nick et al,
In general, the toxicity would not change with the salt involved , although there are exceptions.  For example, when treating hyd rofluoric acid (HF) exposures with calcium salts, the calcium gluconate s alt can be used topically, injected intradermally, or given intravenous ly or interarterially.  However, the calcium chloride salt can onl y be injected intravenously, because it causes severe skin damage and slo ughing if extravasated from a vein or injected intradermally and can cause devastating vascular injury if injected intraarterially.  
Calcium salts are also a good example of the second point.  The dose of the active ingredient can vary significantly with the same volume of di fferent salts.  In the calcium example, the calcium chloride salt& nbsp;in a given volume will have approximately 3 times more Ca+2 ion that the same volume of the calcium gluconate salt.  When treating life- threatening cardiovascular complications of hydrofluoric acid systemic toxi city, it is therefore often wise to choose the calcium chloride salt for intravenous infusion (with precautions against extravaasation), as a much higher dose of calcium ion can provided with the same volume and the same infusion time.
A similar comparison might be made for norepinephrine, but what the relat ionship of dose is between various salt forms in the same volume, I don't have memorized.
Hope this answers the question.
Alan H. Hall, M.D.
President and Chief Medical Toxicologist
Toxicology Consulting and Medical Translating Services, Inc.
Laramie, WY
Clinical Assistant Professor
Colorado School of Public Health
Denver, CO
> Date: Thu, 10 Jun 2010 16:30:45 -0500< BR>> From: tsiakals**At_Symbol_Here**ILLINOIS.EDU
> Subject: [DCHAS-L] toxicity question
> To: DCHAS-L**At_Symbol_Here**LIST.UVM.EDU
> Good afte rnoon all,
> How does toxicity compare from one pharma ceutical salt to another? More specifically, is the toxicity of norepinep hrine the same as norepinephrine bitartrate salt?
> Than ks,
> -Nick

Previous post   |  Top of Page   |   Next post

The content of this page reflects the personal opinion(s) of the author(s) only, not the American Chemical Society, ILPI, Safety Emporium, or any other party. Use of any information on this page is at the reader's own risk. Unauthorized reproduction of these materials is prohibited. Send questions/comments about the archive to
The maintenance and hosting of the DCHAS-L archive is provided through the generous support of Safety Emporium.